(Total Views: 90)
Posted On: 06/04/2025 11:43:34 AM
Post# of 40420
$LUDG - News : Ludwig Enterprises, Inc. (OTC:LUDG), previews its first in a pipeline of non-invasive cancer screening tests powered by mRNA biomarker analysis.
MIAMI, FL / ACCESS Newswire / May 7, 2025 / Ludwig Enterprises, Inc. (the "Company"
, a biotech innovator in mRNA diagnostics and AI-driven health solutions, announced today the initial introduction of its lead product, Revealia Breast™, a non-invasive breast cancer screening test currently in advanced development. This innovative diagnostic tool uses a simple cheek swab to detect cancer-related inflammation early, aiming to identify breast cancer even before physical symptoms appear.
Revealia Breast™ is currently in advanced development, with an expected release in the third quarter of 2025.
Recent data presented at the American Society of Breast Surgeons (ASBS) underscores the urgent need for early detection: patients evaluated through multidisciplinary breast cancer clinics had significantly better outcomes, with 39.7% showing non-invasive disease compared to just 13.2% in traditionally managed groups (1). Revealia Breast™ is designed precisely to facilitate this kind of early diagnosis - and do so more affordably, accessibly, and comfortably than mammograms.
"This is more than just a test - it's a lifeline," said Marvin S. Hausman, MD, Chief Medical Officer at Ludwig Enterprises, Inc. "The earlier we find breast cancer, the better the chance for survival. By analyzing specific mRNA biomarkers from a simple cheek swab, Revealia Breast™ aims to provide that critical early insight, potentially leading to the kind of improved outcomes highlighted in recent clinical findings."
Revealia Breast™ is the first of many early cancer screening tests the Company plans to introduce, targeting most major cancers. Each test is based on the company's proprietary mRNA inflammatory biomarker panel and AI technology, with the mission of enabling earlier, more accurate detection and intervention.
https://finance.yahoo.com/news/revealia-breas...00230.html
MIAMI, FL / ACCESS Newswire / May 7, 2025 / Ludwig Enterprises, Inc. (the "Company"
, a biotech innovator in mRNA diagnostics and AI-driven health solutions, announced today the initial introduction of its lead product, Revealia Breast™, a non-invasive breast cancer screening test currently in advanced development. This innovative diagnostic tool uses a simple cheek swab to detect cancer-related inflammation early, aiming to identify breast cancer even before physical symptoms appear. Revealia Breast™ is currently in advanced development, with an expected release in the third quarter of 2025.
Recent data presented at the American Society of Breast Surgeons (ASBS) underscores the urgent need for early detection: patients evaluated through multidisciplinary breast cancer clinics had significantly better outcomes, with 39.7% showing non-invasive disease compared to just 13.2% in traditionally managed groups (1). Revealia Breast™ is designed precisely to facilitate this kind of early diagnosis - and do so more affordably, accessibly, and comfortably than mammograms.
"This is more than just a test - it's a lifeline," said Marvin S. Hausman, MD, Chief Medical Officer at Ludwig Enterprises, Inc. "The earlier we find breast cancer, the better the chance for survival. By analyzing specific mRNA biomarkers from a simple cheek swab, Revealia Breast™ aims to provide that critical early insight, potentially leading to the kind of improved outcomes highlighted in recent clinical findings."
Revealia Breast™ is the first of many early cancer screening tests the Company plans to introduce, targeting most major cancers. Each test is based on the company's proprietary mRNA inflammatory biomarker panel and AI technology, with the mission of enabling earlier, more accurate detection and intervention.
https://finance.yahoo.com/news/revealia-breas...00230.html
(0)
(0)
